REFERENCES
- Benjamin DK, Jr., Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neu-rodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006; 117 (1): 84–92
- Zaoutis T, Heydon K, Localio R, Walsh T, Feudtner C. Out-comes attributable to neonatal candidiasis. Clin Infect Dis. 2007; 44 (9): 1187–1193
- Manzoni P, Farina D, Leonessa M, d'Oulx E, Galletto P, Mostert M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics. 2006; 118 (6): 2359–2364
- Mermel L, Farr B, Sherertz R, Raad I, O'Grady N, Harris J, et al. Guidelines for the management of intravascular catheterrelated infections. Clin Infect Dis. 2001; 32 (9): 1249–1272
- Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002; 34 (5): 591–599
- Benjamin DK, Jr., Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a criti-cal appraisal of the literature using meta-analytic techniques. Pe-diatrics. 2003; 112 (3 Pt 1):634–640
- Castagnola E, Marazzi MG, Tacchella A, Giacchino R. Broviac catheterrelated candidemia. Pediatr Infect Dis J. 2005; 24 (8): 747
- Justerreicher A, Flidel-Rimon O, Amitay M, Even-Toy S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Mi-crobiol Infect Dis. 2003; 22 (10): 603–607
- Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Souza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007; 44 (10): 1289–1297
- Cuenca-Estrella M. Combinations of antifungal agents in therapy—what value are they? J Antimicrob Chemother. 2004; 54 (5): 854–869
- Manzar S, Kamat M, Pyati S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J. 2006; 25 (3): 282–283
- Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Al-faro B, et al. Caspofungin therapy of neonates with invasive can-didiasis. Pediatr Infect Dis J. 2004; 23 (12): 1093–1097
- Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Toy S, et al. Liposomal amphotericin B (AmBi-some) in the treatment of neonatal candidiasis in yen) low birth weight infants. Infection. 2000; 28 (4): 223–226
- Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Be-dard M. Experience with caspofungin in the treatment of per-sistent fungemia in neonates. J Perinatol. 2005; 25 (12): 770–777
- Cetin H, Yalaz M, Akisu M, Hilmioglu S, Metin D, Kul-tursay N. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia. Pediatr Int. 2005; 47 (6): 676–680
- Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cor-donnier C, Segal BH, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006; 107 (12): 2888–2897
- Cesaro S, Giacchino M, LocateIli F, Spiller M, Buldini B, Castellini C, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable as-pergillosis in pediatric hematological patients. BMC Infect Dis. 2007; 7 (1): 28